BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27462772)

  • 21. Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
    Lu T; Chen F; Yao J; Bu Z; Kyani A; Liang B; Chen S; Zheng Y; Liang H; Neamati N; Liu Y
    J Med Chem; 2024 May; 67(10):8099-8121. PubMed ID: 38722799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor.
    Kozako T; Aikawa A; Ohsugi T; Uchida YI; Kato N; Sato K; Ishitsuka K; Yoshimitsu M; Honda SI
    Eur J Pharmacol; 2019 Dec; 865():172738. PubMed ID: 31614144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
    Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
    Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
    Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
    Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.
    Thakur BK; Dittrich T; Chandra P; Becker A; Lippka Y; Selvakumar D; Klusmann JH; Reinhardt D; Welte K
    Biochem Biophys Res Commun; 2012 Aug; 424(3):371-7. PubMed ID: 22728882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NAD
    Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
    Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
    Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipopolysaccharide-Induced Microglial Neuroinflammation: Attenuation by FK866.
    Xu Y; Yu L; Liu Y; Tang X; Wang X
    Neurochem Res; 2021 May; 46(5):1291-1304. PubMed ID: 33713324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
    Esposito E; Impellizzeri D; Mazzon E; Fakhfouri G; Rahimian R; Travelli C; Tron GC; Genazzani AA; Cuzzocrea S
    J Neuroinflammation; 2012 Apr; 9():66. PubMed ID: 22490786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
    Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
    Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
    Thakur BK; Dittrich T; Chandra P; Becker A; Kuehnau W; Klusmann JH; Reinhardt D; Welte K
    Int J Cancer; 2013 Feb; 132(4):766-74. PubMed ID: 22815158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
    Bai JF; Majjigapu SR; Sordat B; Poty S; Vogel P; Elías-Rodríguez P; Moreno-Vargas AJ; Carmona AT; Caffa I; Ghanem M; Khalifa A; Monacelli F; Cea M; Robina I; Gajate C; Mollinedo F; Bellotti A; Nahimana A; Duchosal M; Nencioni A
    Eur J Med Chem; 2022 Sep; 239():114504. PubMed ID: 35724566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
    Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
    J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fragment-based discovery of a potent NAMPT inhibitor.
    Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
    Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
    Xu R; Yuan Z; Yang L; Li L; Li D; Lv C
    Oncol Rep; 2017 Sep; 38(3):1767-1773. PubMed ID: 28714034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.